Menu
Search
|

Menu

Close
X

Fortress Biotech Inc FBIO.OQ (NASDAQ Stock Exchange Capital Market)

1.21 USD
-- (--)
As of Nov 15
chart
Previous Close 1.21
Open --
Volume --
3m Avg Volume 42,541
Today’s High --
Today’s Low --
52 Week High 5.53
52 Week Low 0.83
Shares Outstanding (mil) 50.53
Market Capitalization (mil) 238.49
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 3 analysts

KEY STATS

Revenue (mm, USD)
FY18
183
FY17
188
FY16
16
FY15
1
EPS (USD)
FY18
-1.364
FY17
-0.684
FY16
-1.378
FY15
-1.236
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.64
Price to Sales (TTM)
vs sector
2.19
5.95
Price to Book (MRQ)
vs sector
3.30
4.89
Price to Cash Flow (TTM)
vs sector
--
22.90
Total Debt to Equity (MRQ)
vs sector
64.97
17.74
LT Debt to Equity (MRQ)
vs sector
56.37
13.15
Return on Investment (TTM)
vs sector
-84.71
14.22
Return on Equity (TTM)
vs sector
-111.07
15.99

EXECUTIVE LEADERSHIP

Lindsay Rosenwald
Chairman of the Board, President, Chief Executive Officer, Since 2013
Salary: $29,254.00
Bonus: --
Eric Rowinsky
Vice Chairman of the Board, Since 2014
Salary: --
Bonus: --
Robyn Hunter
Chief Financial Officer, Since 2017
Salary: --
Bonus: --
Michael Weiss
Executive Vice Chairman - Strategic Development, Since 2014
Salary: $24,324.00
Bonus: --
Lucy Lu
Executive Vice President, Since 2017
Salary: $307,875.00
Bonus: $92,400.00

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

2 Gansevoort St Fl 9
NEW YORK   NY   10014-1667

Phone: +1781.6524500

Fortress Biotech, Inc.(Fortress) is a biopharmaceutical company that acquires, develops and commercializes novel pharmaceutical and biotechnology products. Fortress develops and commercializes products both within Fortress and through certain of its subsidiary companies. Fortress has 11 operating subsidiaries that include: 4 commercial stage programs, 25 development stage programs, targeting 6 therapeutic areas: Immuno-oncology, Hematology, Gene Therapy, Pain Management, Rare Diseases and Dermatology. In addition to its internal development programs, Fortress leverages its biopharmaceutical business expertise and drug development capabilities and provides funding and management services to help the Fortress Companies. Fortress subsidiaries include Aevitas Therapeutics, Avenue Therapeutics, Caelum Biosciences, Cellvation, Inc., Checkpoint Therapeutics, Cyprium Therapeutics, Helocyte, Inc., Journey Medical Corporation, Mustang Bio, National Holdings Corp and Tamid Bio, Inc.

SPONSORED STORIES